Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. (2018)
Attributed to:
OxCD3: Oxford Centre for Drug Delivery Devices
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(18)30332-2
PubMed Identifier: 30001990
Publication URI: http://europepmc.org/abstract/MED/30001990
Type: Journal Article/Review
Volume: 19
Parent Publication: The Lancet. Oncology
Issue: 8
ISSN: 1470-2045